Abstract
A drug challenge test in Parkinson’s disease, such as the levodopa challenge test (LCT), is an easy and generally safe procedure, which has been used by clinicians for various indications. The results of the test have significant implications in the management of patients, from preoperative evaluation for deep brain stimulation to providing the basis for medication adjustments to address motor or non-motor fluctuations and dyskinesias. This paper reviews the different indications and protocols commonly used in an acute LCT. Potential complications of the procedure and an overview of levodopa responsiveness and unresponsiveness are also discussed.
Similar content being viewed by others
Availability of data and material
Not applicable.
Code availability
Not applicable.
References
Kalia LV, Lang AE (2015) Parkinson’s disease. Lancet 386:896–912. https://doi.org/10.1016/S0140-6736(14)61393-3
Anderson E, Nutt J (2011) The long-duration response to levodopa: phenomenology, potential mechanisms and clinical implications. Parkinsonism Relat Disord 17:587–592. https://doi.org/10.1016/j.parkreldis.2011.03.014
Nutt J, Carter J, Woodward W (1995) Long-duration response to levodopa. Neurology 45:1613–1616
Albanese A, Bonuccelli U, Brefel C et al (2001) Consensus statement on the role of acute dopaminergic challenge in Parkinson’s disease. Mov Disord 16:197–201
Merello M, Nouzeilles MI, Arce GP, Leiguarda R (2002) Accuracy of acute levodopa challenge for clinical prediction of sustained long-term levodopa response as a major criterion for idiopathic Parkinson’s disease diagnosis. Mov Disord 17:795–798. https://doi.org/10.1002/mds.10123
Defer GL, Widner H, Marié RM et al (1999) Core assessment program for surgical interventional therapies in Parkinson’s disease (CAPSIT-PD). Mov Disord 14:572–584. https://doi.org/10.1002/1531-8257(199907)14:4%3c572:AID-MDS1005%3e3.0.CO;2-C
Langston JW, Widner H, Goetz CG et al (1992) Core assessment program for intracerebral transplantations (CAPIT). Mov Disord 7:2–13. https://doi.org/10.1002/mds.870070103
Lindvall O, Rehncrona S, Brundin P et al (1989) Human fetal dopamine neurons grafted into the striatum in two patients with severe Parkinson’s disease: a detailed account of methodology and a 6-month follow-up. JAMA Neurol 46:615–631. https://doi.org/10.1001/archneur.1989.00520420033021
Lang AE, Widner H (2002) Deep brain stimulation for Parkinson’s disease: patient selection and evaluation. Mov Disord 17:S94–S101. https://doi.org/10.1002/mds.10149
Machado A, Fernandez HH, Deogaonkar M (2012) Deep brain stimulation: what can patients expect from it? Cleve Clin J Med 79:113–120. https://doi.org/10.3949/ccjm.78gr.11006
Abbruzzese G, Barone P, Bonuccelli U et al (2012) Continuous intestinal infusion of levodopa/carbidopa in advanced Parkinson’s disease: efficacy, safety and patient selection. Funct Neurol 27:147–154
Fernandez HH, Standaert DG, Hauser RA et al (2015) Levodopa-carbidopa intestinal gel in advanced Parkinson’s disease: final 12-month, open-label results. Mov Disord 30:500–509. https://doi.org/10.1002/mds.26123
Rabel C, Le Goff F, Lefaucheur R et al (2016) Subjective perceived motor improvement after acute levodopa challenge in Parkinson’s disease. J Parkinsons Dis 6:779–785. https://doi.org/10.3233/JPD-160906
Schade S, Sixel-Döring F, Ebentheuer J et al (2017) Acute levodopa challenge test in patients with de novo Parkinson’s disease: data from the DeNoPa cohort. Mov Disord Clin Pract 4:755–762. https://doi.org/10.1002/mdc3.12511
Ko P-W, Kang K, Lee H-W (2018) Levodopa-induced respiratory dysfunction confirmed by levodopa challenge test: a case report. Medicine (Baltimore) 97:e12488–e12488. https://doi.org/10.1097/MD.0000000000012488
Fabbri M, Coelho M, Guedes LC et al (2017) Response of non-motor symptoms to levodopa in late-stage Parkinson’s disease: results of a levodopa challenge test. Parkinsonism Relat Disord 39:37–43. https://doi.org/10.1016/j.parkreldis.2017.02.007
Rosqvist K, Odin P, Hagell P et al (2018) Dopaminergic effect on non-motor symptoms in late stage Parkinson’s disease. J Parkinsons Dis 8:409–420. https://doi.org/10.3233/JPD-181380
Berardelli A, Wenning GK, Antonini A et al (2013) EFNS/MDS-ES recommendations for the diagnosis of Parkinson’s disease. Eur J Neurol 20:16–34. https://doi.org/10.1111/ene.12022
Zappia M, Colao R, Montesanti R et al (1997) Long duration response to levodopa influences the pharmacodynamics of short-duration response in Parkinson’s disease. Ann Neurol 42:245–248. https://doi.org/10.1002/ana.410420217
Terroba Chambi C, Rossi M, Bril A et al (2017) Diagnostic value of combined acute levodopa challenge and olfactory testing to predict Parkinson’s disease. Mov Disord Clin Pract 4:824–828. https://doi.org/10.1002/mdc3.12517
Asayama S, Wate R, Kaneko S et al (2013) Levodopa challenge test and 123I-metaiodobenzylguanidine scintigraphy for diagnosing Parkinson’s disease. Acta Neurol Scand 128:160–165. https://doi.org/10.1111/ane.12104
Okun MS, Tagliati M, Pourfar M et al (2005) Management of referred deep brain stimulation failures. Arch Neurol 62:1250. https://doi.org/10.1001/archneur.62.8.noc40425
Suchowersky O, Reich S, Perlmutter J et al (2006) Practice parameter: diagnosis and prognosis of new onset Parkinson disease (an evidence-based review). Neurology 66:968–975. https://doi.org/10.1212/01.wnl.0000215437.80053.d0
National Collaborating Centre for Chronic Conditions (Great Britain) (2017) Parkinson’s disease: national clinical guideline for diagnosis and management in primary and secondary care. Royal College of Physicians, London
Clarke CE (2002) Systematic review of acute levodopa and apomorphine challenge tests in the diagnosis of idiopathic Parkinson’s disease. J Neurol Neurosurg Psychiatry 69:590–594. https://doi.org/10.1136/jnnp.69.5.590
Levin J, Kurz A, Arzberger T et al (2016) ÜBERSICHTSARBEIT: Differenzialdiagnose und Therapie der atypischen Parkinson-syndrome. Dtsch Arztebl Int 113:61–69. https://doi.org/10.3238/arztebl.2016.0061
Vasta R, Nicoletti A, Mostile G et al (2017) Side effects induced by the acute levodopa challenge in Parkinson’s disease and atypical parkinsonisms. PLoS ONE 12:1–6. https://doi.org/10.1371/journal.pone.0172145
Estévez S, Perez-Lloret S, Merello M (2009) Does clinical intolerance to a diagnostic acute levodopa challenge differentiate multiple system atrophy from pd? Int J Neurosci 119:2257–2261. https://doi.org/10.3109/00207450903139721
Müller T, Benz S, Przuntek H (2000) Choice reaction time after levodopa challenge in parkinsonian patients. J Neurol Sci 181:98–103. https://doi.org/10.1016/S0022-510X(00)00436-6
Müller T, Benz S (2002) Quantification of the dopaminergic response in Parkinson’s disease. Parkinsonism Relat Disord 8:181–186. https://doi.org/10.1016/S1353-8020(01)00010-4
Rhew K, Han N, Oh JM (2019) Impact of safety warning on domperidone prescribing for geriatric patients in South Korea: analysis of national insurance claim data. Int J Environ Res Public Health. https://doi.org/10.3390/ijerph16162985
Sethi K (2008) Levodopa unresponsive symptoms in Parkinson disease. Mov Disord 23:S521–S533. https://doi.org/10.1002/mds.22049
Feng T, Li W, Lu L et al (2009) Acute stepwise challenge test with levodopa in treated patients with parkinsonism. Parkinsonism Relat Disord 15:354–358. https://doi.org/10.1016/j.parkreldis.2008.08.010
Castrioto A, Kistner A, Klinger H et al (2013) Psychostimulant effect of levodopa: reversing sensitisation is possible. J Neurol Neurosurg Psychiatry 84:18–22. https://doi.org/10.1136/jnnp-2012-302444
Fabbri M, Coelho M, Abreu D et al (2016) Do patients with late-stage Parkinson’s disease still respond to levodopa? Parkinsonism Relat Disord 26:10–16. https://doi.org/10.1016/j.parkreldis.2016.02.021
Ruonala V, Tarvainen MP, Karjalainen PA et al (2015) Autonomic nervous system response to L-dopa in patients with advanced Parkinson’s disease. Proc Annu Int Conf IEEE Eng Med Biol Soc EMBS 2015:6162–6165. https://doi.org/10.1109/EMBC.2015.7319799
Lucetti C, Logi C, Del Dotto P et al (2010) Levodopa response in dementia with Lewy bodies: a 1-year follow-up study. Parkinsonism Relat Disord 16:522–526. https://doi.org/10.1016/j.parkreldis.2010.06.004
Khor S-P, Hsu A (2007) The pharmacokinetics and pharmacodynamics of levodopa in the treatment of Parkinson’s disease. Curr Clin Pharmacol 2:234–243. https://doi.org/10.2174/157488407781668802
Goetz CG, Tilley BC, Shaftman SR et al (2008) Movement disorder society-sponsored revision of the unified Parkinson’s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 23:2129–2170. https://doi.org/10.1002/mds.22340
Goetz CG, Nutt JG, Stebbins GT (2008) The unified dyskinesia rating scale: presentation and clinimetric profile. Mov Disord 23:2398–2403. https://doi.org/10.1002/mds.22341
Morishita T, Rahman M, Foote KD et al (2011) DBS candidates that fall short on a levodopa challenge test: alternative and important indications. Neurologist 17:263–268. https://doi.org/10.1097/NRL.0b013e31822d1069
Merello M, Gerschcovich ER, Ballesteros D, Cerquetti D (2011) Correlation between the movement disorders society unified Parkinson’s Disease rating scale (MDS-UPDRS) and the Unified Parkinson’s Disease rating scale (UPDRS) during l-dopa acute challenge. Parkinsonism Relat Disord 17:705–707. https://doi.org/10.1016/j.parkreldis.2011.07.002
Warnecke T, Suttrup I, Schröder JB et al (2016) Levodopa responsiveness of dysphagia in advanced Parkinson’s disease and reliability testing of the FEES-Levodopa-test. Parkinsonism Relat Disord 28:100–106. https://doi.org/10.1016/j.parkreldis.2016.04.034
Fabbri M, Marini C, Bisulli F et al (2013) Clinical and polygraphic study of familial paroxysmal kinesigenic dyskinesia with PRRT2 mutation. Epileptic Disord 15:123–127. https://doi.org/10.1684/epd.2013.0569
Lechien JR, Blecic S, Ghosez Y et al (2018) Voice quality and orofacial strength as outcome of levodopa effectiveness in patients with early idiopathic parkinson disease: a preliminary report. J Voice. https://doi.org/10.1016/j.jvoice.2018.04.002
Seiffert P, Derejczyk J, Kawa J et al (2017) Frailty phenotype and the role of levodopa challenge test in geriatric inpatients with mild parkinsonian signs. Biogerontology 18:641–650. https://doi.org/10.1007/s10522-017-9716-6
Gao J, Du LJ, He W et al (2016) Ultrasound strain elastography in assessment of muscle stiffness in acute levodopa challenge test: a feasibility study. Ultrasound Med Biol 42:1084–1089. https://doi.org/10.1016/j.ultrasmedbio.2015.12.014
Chaudhuri KR, Schrag A, Weintraub D et al (2019) The movement disorder society nonmotor rating scale: initial validation study. Mov Disord. https://doi.org/10.1002/mds.27862
Wider C, Russmann H, Villemure J-G et al (2006) Long-duration response to levodopa in patients with advanced parkinson disease treated with subthalamic deep brain stimulation. JAMA Neurol 63:951–955. https://doi.org/10.1001/archneur.63.7.951
Ogawa N (2000) Factors affecting levodopa effects in Parkinson’s disease. Acta Med Okayama 54:95–101
Quattrone A, Zappia M, Aguglia U et al (1995) The subacute levodopa test for evaluating long-duration response in Parkinson’s disease. Ann Neurol 38:389–395. https://doi.org/10.1002/ana.410380308
Parkinson Study Group (2004) Levodopa and the progression of Parkinson’s disease. N Engl J Med 351:2498–2508. https://doi.org/10.1056/NEJMoa033447
Ikebe SI, Harada T, Hashimoto T et al (2003) Prevention and treatment of malignant syndrome in Parkinson’s disease: a consensus statement of the malignant syndrome research group. Parkinsonism Relat Disord 9:47–49. https://doi.org/10.1016/S1353-8020(02)00123-2
Rossi P, Colosimo C, Moro E, Tonali PAA (2001) Acute challenge with apomorphine and levodopa in parkinsonism. Focus Parkinson's Dis 13:60–63. https://doi.org/10.1159/000008142
Funding
This study was supported in part by the Parkinson’s Foundation through its support of the fellowship training of G.S.
Author information
Authors and Affiliations
Contributions
GS performed a detailed review of the literature and undertook the writing of the manuscript. AEL provided critical comments, recommendations, and editorial contributions.
Corresponding author
Ethics declarations
Conflicts of interest
The authors declare no conflict of interest.
Ethics approval
The article is based on previously published studies and patient data and is in line with the journal's ethical guidelines.
Informed consent
Consent to participate: not applicable. Consent for publication: not applicable.
Rights and permissions
About this article
Cite this article
Saranza, G., Lang, A.E. Levodopa challenge test: indications, protocol, and guide. J Neurol 268, 3135–3143 (2021). https://doi.org/10.1007/s00415-020-09810-7
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00415-020-09810-7